Dimerization and dynamics of angiotensin-I converting enzyme revealed by cryoEM and MD simulations

Jordan M. Mancl[1], Xiaoyang Wu[1], Minglei Zhao[2], Wei-Jen Tang[1]

1. Ben-May Department for Cancer Research, The University of Chicago, Chicago, Illinois, United States

2. Department of Biochemistry and Molecular Biology, The University of Chicago, Illinois, United States

Keywords: Angiotensin-I converting enzyme, hypertension, amyloid peptide, cryoEM, all-atom MD simulations.

Author contributions: J.M.M. and W.-J.T., designed the project. X. W. transduced and selected ACE-expression HEK293F cells. J.M.M. and W.-J. T. performed the expression and purification of ACE. J.M.M. performed cryoEM grid preparation, data acquisition and processing assisted by M.Z. and overseen by W.-J. T., and M. Z. J.M.M. built and refined cryoEM structural models and performed heterogeneity analysis. J.M.M. and W.-J. T. performed all-atom MD simulations and analysis. J.M.M. and W.-J.T. wrote the manuscript and all authors contributed to manuscript finalization.

Acknowledgement: We are grateful to Mahira Aragon for grid preparation using Chameleon, Kasahun Neselu for data collection, and Marc Auréle Gilles for assistance with RECOVAR analysis. This work was supported by the NIH grant GM121964 to W.-J. Tang. Some of this work was performed at the National Center for CryoEM Access and Training (NCCAT) and the Simons Electron Microscopy Center located at the New York Structural Biology Center, supported by the NIH Common Fund Transformative High Resolution Cryo-Electron Microscopy program (U24 GM129539,) and by grants from the Simons Foundation (SF349247) and NY State Assembly.

Abstract (175 words)

Angiotensin-I converting enzyme (ACE) regulates the levels of disparate bioactive peptides, notably converting angiotensin-I to angiotensin-II and degrading amyloid beta. ACE is a heavily glycosylated dimer, containing 4 analogous catalytic sites, and exists in membrane bound and soluble (sACE) forms. ACE inhibition is a frontline, FDA-approved, therapy for cardiovascular diseases yet is associated with significant side effects, including higher rates of lung cancer. To date, structural studies have been confined to individual domains or partially denatured cryoEM structures. Here we report the cryoEM structure of the full-length, glycosylated, sACE dimer. We resolved four structural states at 2.99 to 3.65 Å resolution which are primarily differentiated by varying degrees of solvent accessibility to the active sites and reveal the full dimerization interface. We also employed all-atom molecular dynamics (MD) simulations and heterogeneity analysis in cryoSPARC, cryoDRGN, and RECOVAR to elucidate the conformational dynamics of sACE and identify key regions mediating conformational change. We identify differences in the mechanisms governing the conformational dynamics of individual domains that have implications for the design of domain-specific sACE modulators.

Introduction

Angiotensin-I converting enzyme (ACE) is an M2 clan zinc metalloprotease (EC3.4.15.1) located on the plasma membrane and in the extracellular milieu (Bernstein *et al*, 2013; Lubbe *et al*, 2020; Turner & Hooper, 2002). ACE plays a crucial role in the renin-angiotensin system by converting angiotensin I to the potent vasoconstrictor angiotensin II, and in the kinin-kallikrein system by degrading bradykinin, a potent vasodilator. Inhibiting ACE is a primary approach for treating hypertension and is a proven therapy for heart failure, diabetic nephropathy, and other cardiovascular and renal dysfunctions (Herman *et al*, 2024). However, ACE inhibition has known side effects, e.g., dry cough and angioedema, and has been linked to higher rates of lung cancer (Wu *et al.*, 2023). This is partly because ACE also degrades a diverse range of peptides, resulting in complex physiological outcomes due to the interplay in altering levels of these peptides (Bernstein *et al*, 2018; Danziger *et al*, 2023; Herman *et al.*, 2024; Semis *et al*, 2019; Zheng *et al*, 2022). Furthermore, ACE degrades amyloid β (Aβ), which is associated with the progression of Alzheimer's diseases (Hampel *et al*, 2021; Hemming & Selkoe, 2005; Zhang *et al*, 2023; Zou *et al*, 2009). Overexpression of ACE in myelomonocytes substantially reduced Aβ load and prevented Alzheimer's disease-like cognitive decline in mice (Bernstein *et al*, 2014). However, the brains of some Alzheimer's disease patients showed upregulation of the renin-angiotensin system which led to deleterious effects and ACE inhibition was beneficial (Gouveia *et al*, 2022; Qiu *et al*, 2013; Wright *et al*, 2013). These studies indicate that global ACE inhibition could be either beneficial or harmful for individual Alzheimer's patients, and underscores a need for better understanding the molecular mechanisms governing ACE function and substrate selectivity to develop more selective, improved, ACE inhibitors and expand ACE-based therapies (Gouveia *et al.*, 2022; Qiu *et al.*, 2013; Wright *et al.*, 2013).

ACE is a 180 kDa heavily N-linked glycosylated type 1 transmembrane protein with two homologous catalytic domains residing at the N- and C-terminal ends (ACE-N and ACE-C) in its extracellular region (Bernstein *et al.*, 2013; Riordan, 2003; Turner & Hooper, 2002). The ACE extracellular region can be released via proteolytic cleavage near the transmembrane region by ADAM family protease(s), generating soluble ACE (sACE) (English *et al*, 2012). ACE belongs to the cowrin (cowry like) family of zinc metallocarboxypeptidases because its catalytic domain is ellipsoidal and contains a long,

deep, yet narrow catalytic cleft (Gomis-Ruth, 2008). ACE is known to cleave short
peptides, such as angiotensin I (decapeptide) and bradykinin (nonapeptide) by removing
the C-terminal two amino acid residues. Different from the funnelin family of
metallocarboxypeptides that contains a funnel-like cavity, the catalytic cleft of ACE can
accommodate entire oligopeptides and ACE has been shown to cleave multiple discrete
sites on Aβ outside the C-terminal end (Zhou et al., 2009). Thus, it is more accurate to
refer to ACE as an endopeptidase with dipeptidyl carboxylase activity.

Extensive crystallographic studies of ACE-N or ACE-C alone and in complex with
various inhibitors and a catalytic product, angiotensin-II, have elucidated the overall
structures of ACE catalytic domains and molecular details of the catalytic pockets
(Acharya *et at.,* 2024; Corradi *et al.,* 2006; Lubbe *et al.,* 2020; Masuyer *et al.,* 2012;
Natesh *et al.,* 2003b). The structures indicate that each domain is comprised of three sub-
domains and offer insight for the substrate preferences around cleavage sites and the
promiscuity of each domain toward short peptide substrates. Furthermore, they reveal the
orientation of substrate binding sites around scissile bond, indicating that the entire
oligopeptide substrates need to be engulfed into the catalytic chamber of ACE catalytic
domain (Acharya *et al.,* 2024; Masuyer *et al.,* 2012; Natesh *et al.,* 2003a).

However, the catalytic pocket of ACE in the closed state is not large enough to
accommodate the entrance of all its known substrates, particularly Aβ, to permit the
observed cleavage pattern. Thus, similar to other Aβ-degrading proteases, such as insulin
degrading enzyme (IDE), presequence protease (PreP), and neprilysin (NEP), ACE must
undergo a large-scale open-closed transition to capture and degrade larger peptide
substrates such as Aβ (Liang *et al.,* 2022; Malito *et al.,* 2008; Zhang *et al.,* 2018). Recent
open state structures of sACE-N, sACE monomer, and a sACE-N dimer, along with
molecular dynamics (MD) simulations of sACE-C, have begun to reveal the
conformational heterogeneity, though it remains under-studied (Cozier *et al*, 2021; Lubbe
et al, 2022; Phan *et al*, 2020).

The extracellular domains of ACE are readily dimerized in the membrane-bound
and soluble forms. Both the ACE-N and ACE-C domains within the ACE monomer are
catalytically active and each has its own substrate preferences (Bernstein *et al.,* 2011;
Semis *et al.,* 2019; Zou *et al.,* 2009). For example, ACE-N can convert Aβ1-42 to Aβ1-40,

which is less amyloid fibril-prone than Aβ1-42 but ACE-C cannot (Zou *et al.*, 2009).
Accumulating evidence support a complicated interplay between ACE-N and ACE-C
within the ACE dimer. Enzyme kinetics analysis suggests negative cooperativity between
two catalytic domains (Binevski *et al*, 2003; Rice *et al*, 2004; Skirgello *et al*, 2005).
However, ACE also exhibits positive synergy toward Aβ cleavage and allostery to
enhance the activity of its binding partner, bradykinin receptor (Erdos *et al*, 2010; Zou *et*
al., 2009). Recently, cryoEM structures of soluble dimeric apo-sACE were reported
(Lubbe *et al.*, 2022); however, due to the poor resolution/denaturation of sACE-C, only
full-length ACE monomer or dimeric sACE-N was reported. Here, we present four discrete
cryoEM structures of full-length sACE that contain all four catalytic domains (Fig. 1A).
This is followed by cryoEM heterogeneity analysis and all-atom MD simulations. Together,
our analyses provide structural insights into domain interactions, open-closed transitions
of the catalytic domain, and conformational dynamics of soluble dimeric ACE.

Results

Structures of the full-length sACE dimer determined by single particle cryoEM

Soluble human ACE (sACE), which includes the entire extracellular region of ACE,
was expressed in HEK293F cells and purified from culture supernatant using an ion
exchanger (Source Q) followed by size exclusion chromatography (Superdex S200).
Buffer conditions suitable for single particle cryoEM analysis were identified and
optimized using differential scanning fluorometry (Figure S1). Purified sACE was then
vitrified using a Vitrobot, and a dataset of ~3,600 micrographs was collected on a 300
keV Titan Krios equipped with a Gatan K3 camera at the University of Chicago Advanced
Electron Microscopy Facility (Table S1). The data was processed in cryoSPARC v4.4.0
(Figure S2). After filtering ~1.1 million picked particles to ~378K using 2D and 3D
classification, three classes were identified (Figure 1, Figure S2). Of these, ~268K
particles mapped to a dominant 2-domain class reconstructed as an ACE-N dimer, while
~21K particles mapped to a minor 3-domain class containing two ACE-N and only one
ACE-C, reminiscent of the recently published ACE cryoEM structure (Lubbe *et al.*, 2022).
The remaining 89K particles mapped to a full-length ACE dimer containing two ACE-N
and two ACE-C, which was refined to 3.65Å resolution (Figure 1C, S2, Movie S1, Table
S1).

The partial denaturation of macromolecules during vitrification has been attributed

mainly to repeated exposure of the macromolecules to the air-water interface (Glaeser,

2018; Noble *et al*, 2018). The sACE-C domain was shown to be less stable than the ACE-

N domain (Voronov *et al.,* 2002), so we hypothesized that repeated exposure to the air-

water interface could cause preferential denaturation of ACE-C. We have previously

showed that preferential denaturation of human PreP occurred in one of its two

homologous domains and that faster vitrification using Chameleon significantly prevented

such preferential denaturation (Liang *et al*, 2022). Therefore, we collaborated with the

National Center for CryoEM Access and Training (NCCAT) to prepare sACE grids using

Chameleon (Darrow *et al*, 2019). Chameleon preparation reduced the time the sample

spends on the grid before freezing by more than 10-fold. We collected a new dataset of

~18,000 micrographs and our 2D classification revealed a higher percentage of particles

for four-domain classes than those prepared using the Vitrobot (Figure 1B). However, our

3D classification still showed the existence of structures of the ACE-N only dimer and

those containing two ACE-N and one ACE-C (Figure S3). This indicates that the reduction

in vitrification time using Chameleon reduced but did not prevent preferential

denaturation.

From these data, we obtained a map for a consensus ACE structure that achieved

a resolution of 2.8Å. However, while the core region showed excellent map quality, the

map quality for the dynamic regions corresponding to the open-close transition of ACE

catalytic domains was poor, suggesting multiple discrete conformational states exist. We

thus performed 3D classification and reconstructed three distinct conformational states of

full-length apo-ACE at resolutions of 2.99Å, 3.05Å, and 3.15Å (Figure 1C, S3, Movie S2-

4, Table S1). We refer to these ACE dimer structures by their resolutions, namely ACE-

2.99, ACE-3.05, and ACE-3.15, along with the structure from data obtained using the

Vitrobot, ACE-3.65. Given the rich structural information from more than 50 reported

crystal structures of ACE and one recently reported cryoEM study of ACE, below we focus

on the new insights that our ACE dimer structures offer (Acharya *et al*, 2024; Corradi *et*

al, 2006; Lubbe *et al.*, 2020; Lubbe *et al.*, 2022; Masuyer *et al*, 2012; Natesh *et al*, 2003).

The overall structures of sACE dimers and structural insight into dimerization

Soluble ACE has two homologous catalytic domains: ACE-N (amino acids 31-644)

and ACE-C (amino acids 645-1231). Based on the comparison of various catalytic

domains of our ACE dimer structures, we subdivide each catalytic domain of ACE into

three subdomains: D1a, D1b, and D2 for ACE-N, and D3a, D3b, and D4 for ACE-C

(Figure 1A). These three subdomains in either ACE-N or ACE-C form a catalytic chamber.

The catalytic zinc ion is coordinated by the canonical HEXXH motif residing in the D1b

and D3b subdomains (Figure 1A). Four sACE dimer structures manifest as pseudo-

symmetric C2 homodimers across the dimer interface. The dominant symmetry-breaking

features are the degrees of displacement between D1 and D2 or between D3 and D4,

leading to changes in solvent accessibility to the catalytic pockets.

Based on the openness of the catalytic chamber, defined at the distance between

the D1/3a and D2/4 helices that gate access, we classified sACE-N into three

conformational states: open (O), intermediate open (I), and closed (C) (Figure 2A); sACE-

C is significantly less open than sACE-N in our structures, and is only classified into

intermediate (I) and closed (C) states (Figure 2B). The four sACE dimer structures differ

mostly by the degrees of openness of their four catalytic domains (Figure 2C, D). Our

sACE-2.99 and sACE-3.65 structures are globally similar, both contain sACE-N domains

in the open and intermediate states and sACE-C domains in the closed and intermediate

states. In sACE-3.05, both sACE-N domains adopt an open state, while the sACE-C

domains adopt an intermediate and closed state. In the sACE-3.15 structure, one subunit

has both sACE-N and sACE-C adopting a closed conformation, while the other subunit

has an open sACE-N domain and an intermediate sACE-C domain.

Our four cryoEM structures of sACE provide the structural basis for sACE

dimerization. sACE dimerization is mediated by interfaces between D2 subdomains and

D4 subdomains of sACE monomers. The D2 and D4 subdomains generally have much

lower B-factors than the D1 and D3 subdomains (Figure S4). The interaction of the D4-

D4 subdomains is analogous to the D2-D2 interaction, yielding an RMSD of ~1 Å² when

aligned (Figure 3A). The primary source of variation is a general rigid body shift away

from the interaction interface for non-interacting regions in the D4-D4 region compared to

the D2-D2 region. The observed D2-D2 interface is consistent with one of three possible

contacts between sACE-N in the non-crystallographic symmetry mates from previous

crystallographic analysis of sACE-N and the previously published cryoEM structure

(Figure S5). In total, the interface between sACE monomers buries a surface area of

approximately 1,900 Å². Although sACE-N and sACE-C are structurally analogous, their

respective interfaces (sACE-N/N and sACE-C/C) are not equivalent. The sACE-N/N

interface is larger and stronger, burying a surface area of approximately 1,150 Å²,

compared to a buried surface area of approximately 750 Å² for the sACE-C/C interface.

The interface between sACE-N is formed by a hydrophobic core, anchored by a

Y494 π-stacking interaction, and flanked by salt bridges formed by R482 and R487 as

well as E241 and E248 along with a collection of polar and van der Waal contacts (Figure

3B). The dimer interface between two sACE-N domains is completed by glycan-glycan

interactions between the glycans attached to N111, which is consistent with the role of

glycosylation in sACE dimerization (Figure 3C) (Kost *et al*, 2000). However, the central

residues that form the hydrophobic core of the interface between sACE-N are not present

in the interface between sACE-C. Instead, the sACE-C interface is formed by a symmetric

salt bridge between K1096 and E1089, side chain-backbone interactions, and van der

Waals contacts (Figure 3D).

Conformational states of sACE catalytic domains

The comparison of our dimeric sACE cryoEM structures of reveals the

conformational dynamics of sACE catalytic domains. The four sACE dimer structures

represent different combinations of open, intermediate, and closed states of ACE catalytic

domains (Figure 2). By aligning each sACE-N and sACE-C region in our structures to the

D2/4 domain, it becomes clear that our structures represent a continuous gradient of

structural heterogeneity, ranging from the most closed state to the most open state (Figure

S6).

The comparison of sACE-N in its open and closed states reveals the structural

basis for the open-to-closed transition of this domain. Our structures show that when the

tip connecting the two long helices of the D1a subdomain moves away from the D2

subdomain, resulting in the open state, the opposite end of the helix moves closer to the

D2 subdomain, as if the helix were balanced upon a fulcrum (Figure 4A, B). Detailed

structural analysis indicates that the fulcrum is primarily formed by the salt bridge between

two highly conserved residues: E95 in the D1a subdomain and R137 in the D2

subdomain. To stabilize the open state, additional salt bridges are formed, with D218 in

the D2 subdomain pairing with K102 in all cases and occasionally with R125 in the D1a

subdomain (Figure 4A). The loss of this salt bridge in the closed state is compensated for

by the formation of a network of van der Waals interactions between the D1a and D2 subdomains that stabilize the closed state. The transition between open and closed states is likely influenced by the binding of substrates and reaction products during the ACE catalytic cycle. Although a similar fulcrum mechanism is not evident in the sACE-C domain, the connection between the D3a and D2 subdomains would act as a lever to pivot sACE-C from the closed to the open state. The closed state of sACE-C is also stabilized by a network of van der Waals contacts between the D3a and D4 subdomains.

On average, sACE-N is more open than sACE-C, likely due to multiple factors (Figure 2D). In sACE-N, the D1a subdomain is at the N-terminal end of sACE, allowing for a greater range of motion (Figure 4B), while the fulcrum and stabilization mechanisms can maintain sACE-N in a more widely open state (Figure 4A). Conversely, in sACE-C, the motion of the D3a subdomain is constrained by its connection to the D2 subdomain (Figure 4C). Additionally, there are sequence differences at the interface between the three subdomains of sACE-N and sACE-C. In the most closed state—the B chain sACE-C domain of the sACE-3.05 structure—residues from all three subdomains, including I678, V753, V955, and V956, form a hydrophobic latch that stabilizes the closed state (Figure 4D). The hydrophobic latch in sACE-N is weaker because the residue corresponding to V753 has been replaced with a threonine (Figure 4D).

We performed a series of all-atom molecular dynamics (MD) simulations to explore the conformational dynamics of sACE. A total of 8 apo-sACE simulations were conducted, comprising four simulations with non-glycosylated sACE (>1.8 µs each) and four with sACE where all 12 N-linked glycosylation sites have complex glycans (>2 µs each) (Movie S5, S6). Glycan orientations were randomized prior to each simulation to avoid bias. We did not observe a substantial difference in the global conformational dynamics between our sets of simulations with and without glycans. The domain motions of these simulations are summarized in Table S2. Below, we focus on the general features from these simulations.

RMSD analysis reveals that the dominant source of conformational change in our simulations is the open-close transition between the D1/3 and D2/4 domains (Figure S7). The D2/D2 and D4/D4 regions are the most stable, with the bulk of conformational changes localized to the D1/D3 domain. Within the D1/3 domain, we observed that the D1/3a motion was not always correlated with D1/3b or D2/D4, meaning that at a given

time, D1/3a could move along with D1/3b, or with D2/D4, or independently. Consistent with our structural analysis, our MD simulations also indicate that sACE-N displays a much wider range of opening geometries than sACE-C. Most of our MD simulations rapidly closed, preventing an effective comparison of the open vs closed state dynamics. However, the slowest closing simulation did reveal a correlation with our previously described "fulcrum" mechanism of opening for sACE-N (Figure 4A). Our simulation revealed that the K102-D215 interaction was maintained for the entire time that sACE-N adopted an open conformation, yet this interaction was lost when sACE-N transitioned to the closed state (Figure 4E).

The MD simulation of glycosylated ACE provides additional structural insights into the structure and functions of N-linked glycosylation of ACE. Glycosylation is shown to affect the folding, secretion, and stability of ACE (O'Neill *et al*, 2008; Sadhukhan & Sen, 1996). Our MD simulation reveals that the dynamics of 12 N-linked glycans cover a large surface area of ACE, shielding it from environmental insults (Figure S8). Consistent with observations from our Coulomb potential density maps and previously published data, we observed a substantial and persistent inter-subunit interaction between glycans from N111 (Figure 3C). From room mean square fluctuation (RMSF) analysis, glycosylation was found to increase the overall dynamicism of sACE (Figure S9). Furthermore, while there are N-linked glycans near the catalytic chamber, particularly those at the tip of D1a and D3a, they were highly dynamic and did not occlude access to the catalytic chamber. This is consistent with the observation that deglycosylation only modestly increases the enzymatic activity of ACE (Baudin *et al*, 1997; Orth *et al*, 1998; Yu *et al*, 1997).

We also performed three simulations on the non-glycosylated sACE monomer (>1 microsecond each) (Table S2). We observed the expected intra-subdomain open-closed motions in sACE-N and sACE-C that were also observed in the simulations of ACE dimer. We also observed that the motion of sACE-C relative to sACE-N was significantly greater in our monomer simulations compared to our dimer simulations. This suggests that dimerization places significant constraints upon the conformational dynamics of sACE. Previous work has defined the conformational dynamics of sACE from cryoEM data where both sACE-C domains were not resolved. Given our observations from the monomeric and dimeric MD simulations, we endeavored to understand the

conformational heterogeneity present within our cryoEM data to better understand the
impact of dimerization on sACE dynamics.

CryoEM heterogeneity analysis of sACE

CryoEM structures are ensemble averages of many aligned particle images.
Recently, there have been many approaches developed to understand the particle
heterogeneity present within a cryoEM structure as a proxy for molecular motion (Tang *et*
al, 2023). We employed three methods of heterogeneity analysis: cryoDRGN, RECOVAR,
and 3D Variability Analysis (3DVA) (Punjani & Fleet, 2021; Zhong *et al*., 2021; Gilles &
Singer 2024). CryoDRGN employs neural networks to resolve structural heterogeneity in
a nonlinear, multidimensional latent space, while RECOVAR and 3DVA both employ linear
subspace methods. 3DVA finds the linear subspace by an alternating optimization
scheme to capture image variations while RECOVAR utilizes a regularized covariance
estimator to identify subspaces that best capture the distribution of states.

We conducted this analysis on both of our datasets and found the results to agree,
therefore, we focus on the larger, and higher-resolution dataset collected at NCCAT
below. For analysis, the entire particle set, prior to 3D classification and consisting of
~170k particles, was utilized. The particle alignments from the same C1 consensus
refinement were used as input for each of the three methods as current methods to
investigate particle heterogeneity are highly dependent upon initial pose assignment of
individual particles. Globally, all three methods agreed with our ensemble structures, in
that the dominant source of structural variability within our particle population could be
described by the open-closed transition of individual domains, and that sACE-N displayed
more variability than sACE-C.

Initially, we performed 3D variability analysis (3DVA) in cryoSPARC to provide a
direct comparison to the previously published analysis of the partial ACE cryoEM structure
(Punjani & Fleet, 2021) (Figure 5A). Trajectories were reconstructed along the top 5
principal components of variance (Movie S7). Surprisingly, the trajectory describing the
variance along the first principal component vector suggests a dominant inter-domain
motion, where the sACE-N/N region bends towards the sACE-C/C region. The trajectories
along the remaining principal component vectors comprise varying combinations of
individual domains undergoing the open-close transition. Consistent with our previous

observations, the range of presumptive motion in these trajectories is greater in sACE-N

than sACE-C. Previous 3DVA performed on the ACE monomer structure revealed 4 types

of potential motion, termed bending, pivoting, breathing, and jumping (Lubbe *et al.*, 2022).

The breathing motion matches the open-close transition that dominates most of our

principal component vectors, while the bending motion appears to correlate with the

variance described by our top principal component vector. We did not observe any

potential motions reminiscent of the jumping or pivoting motions in our 3DVA.

Furthermore, the magnitude of the bending motion in our 3DVA is substantially less than

previously reported for the partial ACE structure. Together, this highlights a significant

difference in the conformational dynamics between ACE dimer and monomer and

suggests dimerization functions as a key constraint to the conformational dynamics of

sACE.

We then moved on to analyze our data using cryoDRGN, which revealed that the

data formed a single cluster across multiple dimensions (Figure 5B, S10). Trajectories

generated along five principal component vectors of structural variance were dominated

by the open-close transition, primarily in sACE-N (Movie S8). We observed little variance

in sACE-C and, unlike 3DVA, cryoDRGN did not reveal any substantial inter-domain

motions. Faced with this discrepancy between the 3DVA and cryoDRGN results, we

employed a third method, RECOVAR, to further analyze our data. Similar to cryoDRGN,

RECOVAR revealed that our data formed a singular cluster across multiple dimensions

of analysis. Volumes representative of kmeans cluster reconstructions were similarly

consistent with our cryoDRGN results. RECOVAR indicated that the primary source of

structural variance could be explained by the open-close transition, primarily of the sACE-

N domains. With this in mind, we repeated the RECOVAR analysis with a focus mask

around the sACE-N/N region. We then estimated the conformational density by

deconvoluting the multidimensional latent space with a two-dimensional principal

component analysis. The resulting density plot revealed four clusters which corresponded

to different conformations of the sACE-N/N region (Figure 5C). The most populous cluster

corresponded to a state where both sACE-N subunits adopted an open conformation.

The second largest cluster, and the smallest cluster, corresponded to a state where one

sACE-N was open and the other was closed. The discrepancy in population size between

these clusters is likely due to bias in the initial particle poses, rather than a subunit-specific

preference for the open state. The final cluster corresponded to a state where both sACE-
N subunits adopted the closed conformation. We then used RECOVAR to generate a
trajectory through the latent space to predict a potential transition pathway from the
closed-closed state to the open-open state (Movie S9). This trajectory revealed that one
subunit would open, followed by the second, and raised the question of potential allostery
or coordinated motion between the adjacent sACE-N domains. 3DVA, cryoDRGN, and
RECOVAR all appeared to display varying degrees of coordinated motion between sACE
domains, yet this type of analysis lacks an explicit time component, so it is not possible
to draw concrete conclusions regarding coordinated motion. Likewise, while MD
simulations contain an explicit time factor, most of our MD simulations closed quickly, and
did not reopen. Thus, while we did not observe coordinated motion from our simulations,
no conclusion can be reached because of limited intradomain motions. To investigate
coordination between the sACE-N domains, we performed 3D classification in
cryoSPARC with a focus mask on a single sACE-N domain and requested 2 classes
(Figure 5D). The particles were split roughly evenly between the two classes, one
resulting in an open state and the other being closed. We then used these classes for
another round of 3D classification with a focus mask on the opposite sACE-N domain and
again asked for 2 classes. Again, these particles were split roughly evenly among the
classes, leaving us with four similarly sized classes adopting the same conformations as
the clusters revealed by RECOVAR. As a result, we are unable to find any evidence of
coordinated motion between sACE-N domains in the absence of substrate.

<u>Discussion</u>

Our cryoEM and MD simulations analysis of the extracellular regions of dimeric
ACE offers insights into the stability of ACE catalytic domains. We show that ACE dimer
interface consists of three major components, protein-protein interfaces between ACE-N,
glycan-glycan interaction between ACE-N, and protein-protein interface between ACE-C.
The interface between ACE-N, in general, is 50% larger and has higher numbers of
hydrogen bonds and salt bridges than that between ACE-C. The necessity for the stronger
interaction between ACE-N is likely due to that ACE-N is distal to transmembrane helix
so that the additional reinforcement is required. The weaker interaction and lack in the
contribution from glycan in the interface between ACE-C could also explain the observed
preferential denaturation of ACE-C despite the high structural similarity between ACE-N

and ACE-C. The denaturation is likely due to the exposure to air-water interface during vitrification, a common issue in single particle cryoEM analysis (Glaeser, 2018; Noble *et al.*, 2018). We have partially overcome the denaturation issue of ACE-C by optimizing the buffer pH to increase the melting temperature and using the faster plunging time during vitrification afforded by Chameleon to reduce the exposure to air-water interface (Figure 1). However, we did not completely prevent the preferential denature of ACE-C during vitrification.

ACE is part of a family of proteases capable of effectively degrading Aβ. This family includes M16 metalloproteases like IDE and PreP, and M13 metalloproteases such as neprilysin and endothelin converting enzyme. Integrative structural analysis has demonstrated how IDE employs conformational dynamics, charge, and secondary structure complementarity to selectively capture peptide substrates into its sizable catalytic chamber, subsequently unfolding and degrading amyloidogenic peptides such as insulin and Aβ, without degrading structurally similar yet non-amyloidogenic peptides (Malito *et al*, 2008; Tang, 2016; Zhang *et al*, 2018). The other mentioned enzymes also belong to this group of chamber-containing proteases, known as cryptidases (Liang *et al*, 2021; Liang *et al.*, 2022; Malito *et al.*, 2008). Similar to cryptidases, structural analysis reveals that ACE must undergo an open-closed transition to capture, engulf, and degrade its oligopeptide substrates, such as angiotensin 1 and bradykinin.

Our apo-ACE structures and MD simulations identify a fulcrum mechanism that governs the open-closed transition of ACE-N, while the interplay between ACE-N and the D3a domain likely plays a crucial role in this transition. Analogous to the binding of MB60, a PreP inhibitor, to the hydrophobic pocket to trigger the open to closed transition, factors such as binding of substrates and ACE inhibitors may alter the balance, leading to the regulation of ACE activity (Liang *et al.*, 2022). We also observe that the catalytic pocket of the ACE catalytic domain is not large enough to engulf the entire Aβ. Additionally, the distances between the domains (ACE-N to ACE-C, ACE-N to ACE-N, or ACE-C to ACE-C) are too large for these domains to bind Aβ simultaneously (Chen *et al*, 2017). Therefore, ACE likely employs a different mechanism from IDE and PreP to selectively bind and degrade Aβ. Future integrative structural studies await to reveal how ACE selectively recognizes and degrades a diverse array of substrates.

Single particle cryoEM holds significant promise for revealing the conformational

dynamics of biological macromolecules from embedded heterogeneity. Consequently,

cryoEM heterogeneity analysis is an active and rapidly evolving field providing insights

into the conformational dynamics and allostery of macromolecules (Tang *et al.*, 2023).

However, many challenges exist in using cryoEM heterogeneity analysis due, in part, to

the low signal-to-noise ratio in observed micrographs. Often, these analyses address

questions difficult or impossible to tackle experimentally, leaving no ground truth for

validation. We encounter such challenges in our heterogeneity analysis as well.

Consistent with our single particle cryoEM structural analysis, we observed the expected

intradomain open-closed transition using cryoDRGN, cryoSPARC 3DVA, RECOVAR, and

all-atom MD simulation. Surprisingly, we did not observe such motion using cryoSPARC

3DFlex, a neural network-based method analyzing our cryoEM data of sACE (Punjani &

Fleet, 2023). Central to the working of cryoSPARC 3DFlex is the generation of a

tetrahedral mesh used to calculate deformations within the particle population. Proper

generation of the mesh is critical for obtaining useful results and must often be determined

empirically. Despite several attempts, we were unable to obtain mesh conditions suitable

to observe any open-close transition, illustrating a limitation of cryoSPARC 3DFlex.

The interplay between ACE-N and ACE-C within the ACE dimer has complicated

consequences for ACE functions, showing negative cooperativity for enzymatic activities

while exhibiting positive synergy in Aβ cleavage by ACE-N and activity at the bradykinin

receptor (Binevski *et al.*, 2003; Erdos *et al.*, 2010; Rice *et al.*, 2004; Skirgello *et al.*, 2005;

Zou *et al.*, 2009). Understanding the conformational dynamics in both inter- and intra-

domain motions of the extracellular regions of the ACE dimer holds promise for designing

ACE modulators to improve and broaden the therapeutic use of ACE modulation. Our

cryoEM heterogeneity analysis has revealed coordinated open-closed transitions across

four catalytic domains using cryoDRGN and cryoSPARC 3DVA, which could potentially

provide the molecular basis for ACE allostery (Figure 5A,B, Movies S7,8). However, our

RECOVAR analysis reveals independent motion of two ACE-N domains, not the

coordinated motion revealed by cryoDRGN and cryoSPARC 3DVA (Figure 5C).

Furthermore, our focused classification using cryoSPARC failed to reveal a profound

association between specific conformational states of the ACE catalytic domains, an

expectation from the trajectories revealed by cryoDRGN and cryoSPARC 3DVA (Figure
5D).

The first principal component trajectory in our 3DVA analysis revealed a significant
potential interdomain motion between sACE-N/N and sACE-C/C, yet cryoDRGN and
RECOVAR did not reveal any inferred motions of similar magnitude. Notably, the
trajectory revealing this potential interdomain motion in 3DVA was absent any variability
in the sACE-N open/close transition. In our study, this conformational heterogeneity
appears to stem from subtle yet significant conformational differences between the two
chains within an ACE dimer and the inability of cryoSPARC to properly align these
conformationally distinct chains (Figure S11). CryoDRGN and RECOVAR revealed
smaller magnitudes of potential interdomain motions, which were often accompanied by
various combinations of individual domains opening and/or closing. This suggests that
the apparent discrepancy in the magnitude of inferred interdomain motion could be a
result of the different theoretical approaches of dimensionality reduction and trajectory
generation employed by the respective methods of analysis and underscores the
importance of incorporating multiple methods of analysis in the absence of a singular
"gold-standard" of heterogeneity analysis.

Advances in single-particle cryoEM analysis have enabled detailed structural
examination of the extracellular domains of the ACE dimer. Beyond its implications for
future drug discovery efforts aimed at enhancing ACE-based therapies, ACE can serve
as a valuable model of a multi-domain glycoprotein for studying methods to preserve
sample integrity, particularly due to the high propensity of ACE-C to denature during
vitrification. Furthermore, considering the aforementioned challenges and caveats, we
propose that, due to its size, biomedical importance, and the complexity of its motions,
ACE also represents an excellent model system for evaluating and improving cryoEM
heterogeneity analysis.

Experimental procedures

Expression of human sACE: Human 293T and 293F cells were maintained in DMEM +
10% fetal calf serum (FCS). The lentiviral plasmid for the expression of the extracellular
domain of human ACE (sACE, aa 1-1231) that contains a 6-histidine tag at its C-terminus
was made by Vectorbuilder and co-transfected with helper plasmids to human 293T cells

for lentiviral production. Human 293F cells were infected with the resulting virus and

selected for stable sACE expression. 293F that stably expressed sACE grew poorly in

Free-style 293 media (ThermoFisher 12338018). Thus, for ACE production, 293F cells

that stably expressed sACE were first grown in DMEM+10% FCS at 37°C and gradually

shifted into Free-style 293 media by reducing FCS by first in Free-style 293 media + 2%

FCS and then to media without FCS. These cells were then shifted to and maintained in

30°C for 3-5 days for ACE production to reduce proteolysis.

Purification of soluble human ACE: Culture supernatant was centrifuged at 3,000xg for

5 min, diluted 10-fold with 25 mM Tris-HCl pH 8, filtered, and run over a Source Q column

pre-equilibrated with 25 mM Tris-HCl pH 8. Column was washed to baseline with Tris-HCl

pH 8 and bound protein was eluted with a linear gradient of NaCl to 1 M. sACE containing

fractions were pooled and EDTA was added to 10 mM to strip the catalytic zinc ion.

Sample was concentrated and run over a Superdex S200 SEC column pre-equilibrated

with the desired cryoEM buffer.

Differential scanning fluorometry (DSF): To optimize the grid making conditions,

differential scanning fluorimetry was applied to screen 96 buffers conditions. DSF was

performed with 3 mg/ml sACE and 10X Sypro Orange in 20 µl buffers in a Thermo Fisher

Step ONE RT-PCR thermocycler. Using the melting temperature and slope as selective

criteria, 25 mM citrate pH 5.5, 25 mM sodium phosphate pH 5.5, 150 mM NaCl, 10 mM

EDTA was identified as the ideal buffer condition and used for all subsequent cryoEM

experiments.

CryoEM data collection and processing: Peak fractions were collected off the SEC

column and used to immediately prepare grids, resulting in a protein concentration of ~4.5

mg/ml. Quantifoil R1.2/1.3 Cu200 grids were glow-discharged in air and grids were

prepared by Vitrobot mark 3. 3.5 µl of sample was applied to the grid in the chamber with

100% humidity, 25°C. Excess sample was blotted for 1 sec, blot force 2, and grids were

plunge frozen in liquid ethane. All images were acquired using a Titan Krios microscope

(FEI) operated at 300KeV with a Gatan K3 direct electron detector. A dataset of ~3,600

micrographs was collected at The University of Chicago Advanced Electron Microscopy

facility. The dataset was processed using cryoSPARC (Figure S1) (Punjani *et al*, 2017).

Briefly, a four-domain sACE dimer model was generated using sACE-N dimer and sACE

monomer and adjusting the distance between ACE-C domains to avoid steric clashes as

a template for particle picking (Lubbe *et al.*, 2022). After template picking, 1.1 million particles were extracted with a box size of 360 pixels. Several rounds of 2D classification were used to remove junk particles. ~577K particles were processed in successive rounds of *ab initio* reconstruction and heterogeneous refinement. sACE grids were also prepared using Chameleon and collected a dataset of ~19,000 micrographs at the National Center for CryoEM Access and Training. For those, Quantifoil Active R 1.6/0.9 Cu/Rh 300 were coated with gold using a Safematic CCU-010 Compact Coating Unit. Briefly, grids were placed nanowire side down on a glass slide, gold disks were sputtered with a 35 nm target thickness at 1.5×10^{-2} Torr, and a process current of 30 mA. Grids were glow discharged with air at 12mA for 80 secs using the internal Chameleon glow discharger. The grids were plunged at 160 to 180 milliseconds. All images were acquired using a Titan Krios microscope (FEI) operated at 300KeV with a Gatan K3 direct electron detector (Gatan). Images were automatically acquired using Leginon (Suloway et al., 2005) using collection parameters as shown in Table S1. This dataset was processed in cryoSPARC (Figure S2). Briefly, templates were generated from our full-length ACE structure described above using vitrobot-prepared grids. Micrographs with a max CTF value worse than 4Å were removed from the dataset, leaving ~12,000 micrographs for template picking, which yielded 10.7 million particles. The particle set was trimmed to ~2.8 million based on quality metrics and run through 2 rounds of 2D classification, reducing the particle number to ~660,000. 2D classes were dominated by 4 domain views, and yielded a much greater diversity of views, indicating that Chameleon preparation produced a dramatic improvement in particle quality. Initial 3D homogeneous refinement reached 3.6 Å, matching the previous final structure. Four maps from 3D classes that contains all four catalytic domains of ACE, one from particles derived from grids prepared by using vitrobot and three from those prepared by using Chameleon, were used for structure building using Chimera and Coot and the structure was refined using Phenix real space refinement. Structural analysis was performed using PYMOL and Chimera.

Heterogeneity analysis: All heterogeneity analysis was performed on the full final particle set, encompassing all of the NCCAT structures. Initially, cryoSPARC 3DVA was performed on both the NCCAT- and UChicago-collected datasets and results were found to be consistent, so the NCCAT-collected dataset was used for further analysis, given its higher particle number and quality. Input particle poses for each method of heterogeneity

analysis were derived from the same C1 refinement job in cryoSPARC, which reached
2.88 Å. 3DVA was used to solve the top 5 modes of variance with a filter resolution of 6
Å. Particles were downsampled ~3x to a box size of 128 pixels in cryoDRGN to speed up
processing. The same downsampled particle set was used for both cryoDRGN and
RECOVAR. CryoDRGN was run with default parameters and the analysis was performed
on the top 5 principal components for direct comparison to cryoSPARC 3DVA. RECOVAR
pipeline.py was initially run on the full sACE structure. Reconstructions representative of
kmeans cluster centers revealed the dominant source of structural variability to be the
open-close transition in sACE-N. As a result, RECOVAR was run again with a focus mask
on sACE-N/N and a zdim=4. Conformational density was estimated with a 2-dimensional
PCA, and an index value of 3 was chosen for further analysis. The points in latent space
representing the top 12 stable conformational states were estimated from the top 20% of
particles and representative volumes were generated. The generated states populated
four clusters and the 12 states were simplified to 4 distinct conformations where sACE-
N/N adopted the open-open (OO), open-closed (OC), closed-open (CO), and closed-
closed (CC) states (Figure 5C). We then generated a trajectory through the latent space
using the OO and CC representative volumes as endpoints (Movie S7).

All-atom MD simulations and analysis: The sACE-3.65 structure was used to initiate
all MD simulations. For the glycosylated sACE simulations, N-linked glycans were built
onto all 12 known N-linked glycosylation sites (residues 38, 54, 74, 111, 146, 318, 445,
509, 677, 695, 714, 760) with the complex glycan BGLC-BGLC-BMAN-AMAN-BGLC-
ANE5-AMAN-BGLC-BGAL-ANE5-AFUC using CHARMM-GUI (Lee *et al*, 2016).
Simulations were prepared in QwikMD or CHARMM-GUI and run at pH 7, 150 mM NaCl,
310 K, 1 atm with periodic boundary conditions in NAMD3.0 using the University of
Chicago Beagle3 partition (Phillips *et al*, 2020). Explicit solvent was described with the
TIP3P model (Jorgensen *et al*, 1983). Data was analyzed in VMD 1.9.4 (Humphrey *et al*,
1996).

Figure + figure legends:

Figure 1: CryoEM analysis of human ACE dimer. (A) Diagram for the key features of domain on primary sequence of human ACE. To avoid confusion existing in the numbering of ACE structures, we number ACE based on Uniprot P12821-1. D1a and D3a domains, also called "lid" encompasses residues 31-127 and aa 645-725, respectively. D1b and D3b domains each have two discrete segments; residues 292-465 and 525-603 for D1b and residues 897-1060 and 1120-1200 for D3b. D2 encompasses three discrete segments, residues 128-291, 466-524, and 604-644 while D4 domain encompasses residues 726-896, 1061-1119, and 1201-1231. sp = signal peptide. asterisk = zinc binding motif. The construct used in this study comprises residues 1-1231, which we refer to as the soluble region of ACE (sACE). Colored by sub-domain: D1a cyan, D1b aqua, D2 pink, D3a light blue, D3b green, D4 magenta. (B) 2D classification of human sACE particles from grids made by vitrobot and Chameleon. Clear four domain classes visible in the Chameleon-derived classification are boxed in red, similar views are lacking in the vitrobot dataset. (C) Full-length sACE 3D volumes, colored by sub-domain as in (A). Glycan density is shown in gray. See Figure S2 for vitrobot-prepared data processing details, Figure S3 for Chameleon-prepared data processing details and Table S1 for data refinement statistics.

Figure 2: Overall structure of human ACE. (A) Overlay comparing sACE-N states highlighting the structure differences between the closed (C), intermediate (I), and open (O) states. (B) Overlay comparing sACE-C states highlighting the structure differences between the closed (C), and intermediate (I) states. We define the state based on the distance between the edge of the D2/4 domain bordering the catalytic cleft (residues 150-155 or 750-755) and the tip of the D1/3a region (residues 70-80 or 676-686): closed <15 Å, intermediate >15 Å and <19 Å, open >19 Å. (C) Overall dimer comparisons. (D) Table of openness measurements for each domain per structure.

Opening distance (Å)	sACE-2.99		sACE-3.05		sACE-3.15		sACE-3.65	
	Chain A	Chain B	Chain A	Chain B	Chain A	Chain B	Chain A	Chain B
ACE-N	23.4 (O)	17.7 (I)	22.5 (O)	22.1 (O)	14.1 (C)	20.2 (O)	20.6 (O)	16.2 (I)
ACE-C	14.4 (C)	18.0 (I)	17.9 (I)	13.9 (C)	13.7 (C)	17.0 (I)	14.4 (C)	15.9(I)

Figure 3: sACE dimerization interfaces. (A) Overlay comparing sACE-N/N interface (blue)
and sACE-C/C (yellow) interfaces. Interfaces adopt the same secondary structure but
interacting residues vary between them. (B) Residue-specific interactions at the sACE-
N/N interface, see text for details. (C) Unsharpened Coulomb potential density map (cyan)
showing density corresponding to glycan-glycan interaction from N111 as part of sACE-
N/N interface. Sharpened map is shown in magenta for reference. (D) Residue-specific
interactions in the sACE-C/C interface, see text for details.

Figure 4: Structural mechanism of the sACE open/close transition. (A) sACE-N overlay
comparing the open (colored in left panel, transparent gray in right panel) and closed
(transparent gray in left panel, colored in right panel) states in detail. The open state is
stabilized by interaction between residues in the D1a (cyan) and D2 (pink) regions that,
notably K102-D218. In the closed state, the K102-D218 interaction is broken. (B) Overlay
of the sACE-N open (cyan) and closed (pink) states showing the range of motion. The
D1a region rotates about a fulcrum region described in (A), while the D1b region moves
as a rigid body. (C) Overlay of sACE-C closed (light blue) and intermediate (yellow) states.
Unlike sACE-N, the "top" of the D3a region is constrained by its connection to sACE-N

and largely immobile. The primary source of opening is only the motion of the D3a tip. We did not observe any open state structures of sACE-C, suggesting a smaller range of motion relative to sACE-N. (D) Comparison of the hydrophobic "latch" region formed in the closed state between residues of the D1/3a, D1/3b, and D2/D4 domains. V753 in sACE-C has been replaced by T153 in sACE-N, suggesting that the closed state in sACE-N may be less stabilized than the sACE-C closed state. (E) Example all-atom MD simulation tracking the openness of one sACE-N region (black line) and this distance between K102 and D218 (red line). These residues form a salt bridge early in the simulation when sACE-N is open (left inset) but the interaction breaks as sACE-N transitions to the closed state (right inset). Distance measurements for MD simulations were consistently greater than distance values in our static structures and cannot be directly compared to Figure 2.

Figure 5: CryoEM heterogeneity analysis. (A) Visualization of the structural changes revealed by cryoSPARC 3DVA trajectories calculated along two principal components (PCs) of structural variance. Starting states are showing in cyan, ending states in gray. PC 0 reveals a large, inter-domain bending motion accompanied by the open/close transition in sACE-C. PC 1 and the remaining PCs are dominated by the open/close transition of individual regions. See Table S3, and Movie S7 for additional details. (B) Visualization of the structural changes revealed by the cryoDRGN trajectories calculated along two PCs of structural variance. Starting states are shown in cyan, ending states in gray. PCs are dominated by the open/close transition of individual regions. See Table S3, and Movie S8 for additional details. (C) Analysis in RECOVAR with a focus mask on

sACE-N/N reveals that particles adopt roughly four clusters within the latent space (heat

map of particle density) corresponding to the open-open (OO, white square), open-closed

(OC, white dot), closed-open (CO, white dot) and closed-closed (CC, white star) states of

sACE-N/N. A trajectory estimating the path through latent space corresponding to the

structural transition from sACE-N/N CC state to the OO state (blue points) suggests that

individual sACE regions transition at different rates. See Movie S9 for trajectory. (D)

Focused 3D classification was performed in cryoSPARC to explore evidence of

coordinated motion between sACE-N regions. 3D classification focusing on one sACE-N

region revealed 2 roughly equal classes of particles: open and closed. Subsequent 3D

classification focused on the other sACE-N region again revealed 2 roughly equal

classes, suggesting the lack of coordinated motion between sACE-N regions in the

absence of substrate.

Data availability:

Unprocessed micrographs, particle stacks, and associated pose/CTF information have been deposited to EMPIAR under the accession numbers: EMPIAR-12181 (Vitrobot-prepared grids) and EMPIAR-12484 (Chameleon-prepared grids)

EM structures and maps have been deposited to the EMDB and PDB, respectively, under the following accession numbers:

sACE-2.99: 9D5S and EMD-46581

sACE-3.05: 9D5M and EMD-46579

sACE-3.15: 9D55 and EMD-46574

sACE-3.65: 9CLX and EMD-45733

References:

References:

Acharya KR, Gregory KS, Sturrock ED (2024) Advances in the structural basis for angiotensin-1
converting enzyme (ACE) inhibitors. *Bioscience Rep* 44

Baudin B, Alves N, Pilon A, Beneteau-Burnat B, Giboudeau J (1997) Structural and biological roles of
glycosylations in pulmonary angiotensin I-converting enzyme. *Glycobiology* 7: 565-570

Bernstein KE, Khan Z, Giani JF, Cao DY, Bernstein EA, Shen XZ (2018) Angiotensin-converting enzyme
in innate and adaptive immunity. *Nat Rev Nephrol* 14: 325-336

Bernstein KE, Koronyo Y, Salumbides BC, Sheyn J, Pelissier L, Lopes DHJ, Shah KH, Bernstein EA,
Fuchs DT, Yu JJY *et al* (2014) Angiotensin-converting enzyme overexpression in myelomonocytes
prevents Alzheimer's-like cognitive decline. *J Clin Invest* 124: 1000-1012

Bernstein KE, Ong FS, Blackwell WLB, Shah KH, Giani JF, Gonzalez-Villalobos RA, Shen XZ, Fuchs S
(2013) A Modern Understanding of the Traditional and Nontraditional Biological Functions of
Angiotensin-Converting Enzyme. *Pharmacol Rev* 65: 1-46

Binevski PV, Sizova EA, Pozdnev VF, Kost OA (2003) Evidence for the negative cooperativity of the two
active sites within bovine somatic angiotensin-converting enzyme. *Febs Lett* 550: 84-88

Chen GF, Xu TH, Yan Y, Zhou YR, Jiang Y, Melcher K, Xu HE (2017) Amyloid beta: structure, biology and
structure-based therapeutic development. *Acta Pharmacol Sin* 38: 1205-1235

Corradi HR, Schwager SLU, Nchinda AT, Sturrock ED, Acharya KR (2006) Crystal structure of the N
domain of human somatic angiotensin I-converting enzyme provides a structural basis for domain-
specific inhibitor design. *Journal of Molecular Biology* 357: 964-974

Cozier GE, Lubbe L, Sturrock ED, Acharya KR (2021) Angiotensin-converting enzyme open for
business: structural insights into the subdomain dynamics. *FEBS J* 288: 2238-2256

Danziger R, Fuchs DT, Koronyo Y, Rentsendorj A, Sheyn J, Hayden EY, Teplow DB, Black KL, Fuchs S,
Bernstein KE *et al* (2023) The effects of enhancing angiotensin converting enzyme in
myelomonocytes on ameliorating Alzheimer's-related disease and preserving cognition. *Front
Physiol* 14: 1179315

Darrow MC, Moore JP, Walker RJ, Doering K, King RS (2019) Chameleon: Next Generation Sample
Preparation for CryoEM based on Spotiton. *Microscopy and Microanalysis* 25: 994-995

English WR, Corvol P, Murphy G (2012) LPS activates ADAM9 dependent shedding of ACE from
endothelial cells. *Biochem Bioph Res Co* 421: 70-75

Erdos EG, Tan F, Skidgel RA (2010) Angiotensin I-converting enzyme inhibitors are allosteric
enhancers of kinin B1 and B2 receptor function. *Hypertension* 55: 214-220

Glaeser RM (2018) Proteins, interfaces, and cryo-EM grids. *Curr Opin Colloid In* 34: 1-8

Gomis-Ruth FX (2008) Structure and Mechanism of Metallocarboxypeptidases. *Critical Reviews in
Biochemistry and Molecular Biology* 43: 319-345

Gouveia F, Camins A, Ettcheto M, Bicker J, Falcao A, Cruz MT, Fortuna A (2022) Targeting brain Renin-
Angiotensin System for the prevention and treatment of Alzheimer's disease: Past, present and
future. *Ageing Res Rev* 77

Hampel H, Hardy J, Blennow K, Chen C, Perry G, Kim SH, Villemagne VL, Aisen P, Vendruscolo M,
Iwatsubo T *et al* (2021) The Amyloid-β Pathway in Alzheimer's Disease. *Mol Psychiatr* 26: 5481-5503

Hemming ML, Selkoe DJ (2005) Amyloid beta-protein is degraded by cellular angiotensin-converting
enzyme (ACE) and elevated by an ACE inhibitor. *J Biol Chem* 280: 37644-37650

Herman LL, Padala SA, Ahmed I, Bashir K (2024) Angiotensin-Converting Enzyme Inhibitors (ACEI).
In: *StatPearls*, Treasure Island (FL) ineligible companies. Disclosure: Sandeep Padala declares no
relevant financial relationships with ineligible companies. Disclosure: Intisar Ahmed declares no
relevant financial relationships with ineligible companies. Disclosure: Khalid Bashir declares no
relevant financial relationships with ineligible companies.

Humphrey W, Dalke A, Schulten K (1996) VMD: visual molecular dynamics. *J Mol Graph* 14: 33-38,
27-38

Jorgensen WL, Chandrasekhar J, Madura JD, Impey RW, Klein ML (1983) Comparison of Simple
Potential Functions for Simulating Liquid Water. *J Chem Phys* 79: 926-935

Kost OA, Bovin NV, Chemodanova EE, Nasonov VV, Orth TA (2000) New feature of angiotensin-
converting enzyme: carbohydrate-recognizing domain. *J Mol Recognit* 13: 360-369

Lee J, Cheng X, Swails JM, Yeom MS, Eastman PK, Lemkul JA, Wei S, Buckner J, Jeong JC, Qi YF *et al*
(2016) CHARMM-GUI Input Generator for NAMD, GROMACS, AMBER, OpenMM, and
CHARMM/OpenMM Simulations Using the CHARMM36 Additive Force Field. *J Chem Theory Comput*
12: 405-413

Liang WG, Mancl JM, Zhao M, Tang WJ (2021) Structural analysis of Mycobacterium tuberculosis M13
metalloprotease Zmp1 open states. *Structure* 29: 709-720

Liang WG, Wijaya J, Wei H, Noble AJ, Mancl JM, Mo S, Lee D, Lin King JV, Pan M, Liu C *et al* (2022)
Structural basis for the mechanisms of human presequence protease conformational switch and
substrate recognition. *Nat Commun* 13: 1833

Lubbe L, Cozier GE, Oosthuizen D, Acharya KR, Sturrock ED (2020) ACE2 and ACE: structure-based
insights into mechanism, regulation and receptor recognition by SARS-CoV. *Clin Sci* 134: 2851-2871

Lubbe L, Sewell BT, Woodward JD, Sturrock ED (2022) Cryo-EM reveals mechanisms of angiotensin
I-converting enzyme allostery and dimerization. *EMBO J* 41: e110550

Malito E, Hulse RE, Tang WJ (2008) Amyloid β-degrading cryptidases: insulin degrading enzyme,
presequence peptidase, and neprilysin. *Cell Mol Life Sci* 65: 2574-2585

Masuyer G, Schwager SLU, Sturrock ED, Isaac RE, Acharya KR (2012) Molecular recognition and
regulation of human angiotensin-I converting enzyme (ACE) activity by natural inhibitory peptides.
Sci Rep 2: 717

Natesh R, Schwager SLU, Sturrock ED, Acharya KR (2003) Crystal structure of the human
angiotensin-converting enzyme-lisinopril complex. *Nature* 421: 551-554

Noble AJ, Wei H, Dandey VP, Zhang Z, Tan YZ, Potter CS, Carragher B (2018) Reducing effects of
particle adsorption to the air-water interface in cryo-EM. *Nat Methods* 15: 793-795

O'Neill HG, Redelinghuys P, Schwager SLU, Sturrock ED (2008) The role of glycosylation and domain
interactions in the thermal stability of human angiotensin-converting enzyme. *Biol Chem* 389: 1153-
1161

Orth T, Voronov S, Binevski P, Saenger W, Kost O (1998) Glycosylation of bovine pulmonary
angiotensin-converting enzyme modulates its catalytic properties. *Febs Lett* 431: 255-258

Phan TTV, Heo SY, Jung WK, Yi M (2020) Spontaneous Hinge-Bending Motions of Angiotensin I
Converting Enzyme: Role in Activation and Inhibition. *Molecules* 25: 1288

Phillips JC, Hardy DJ, Maia JDC, Stone JE, Ribeiro JV, Bernardi RC, Buch R, Fiorin G, Hénin J, Jiang W
et al (2020) Scalable molecular dynamics on CPU and GPU architectures with NAMD. *J Chem Phys*
153

Punjani A, Fleet DJ (2021) 3D variability analysis: Resolving continuous flexibility and discrete
heterogeneity from single particle cryo-EM. *J Struct Biol* 213

Punjani A, Fleet DJ (2023) 3DFlex: determining structure and motion of flexible proteins from cryo-
EM. *Nature Methods* 20: 860-+

Punjani A, Rubinstein JL, Fleet DJ, Brubaker MA (2017) cryoSPARC: algorithms for rapid unsupervised
cryo-EM structure determination. *Nat Methods* 14: 290-296

Qiu WQ, Mwamburi M, Besser LM, Zhu HH, Li HJ, Wallack M, Phillips L, Qiao LY, Budson AE, Stern R
et al (2013) Angiotensin Converting Enzyme Inhibitors and the Reduced Risk of Alzheimer's Disease
in the Absence of Apolipoprotein E4 Allele. *J Alzheimers Dis* 37: 421-428

Rice GI, Thomas DA, Grant PJ, Turner AJ, Hooper NM (2004) Evaluation of angiotensin-converting
enzyme (ACE), its homologue ACE2 and neprilysin in angiotensin peptide metabolism. *Biochem J*
383: 45-51

Riordan JF (2003) Angiotensin-I-converting enzyme and its relatives. *Genome Biol* 4: 225

Sadhukhan R, Sen I (1996) Different glycosylation requirements for the synthesis of enzymatically
active angiotensin-converting enzyme in mammalian cells and yeast. *J Biol Chem* 271: 6429-6434
Semis M, Gugiu GB, Bernstein EA, Bernstein KE, Kalkum M (2019) The Plethora of Angiotensin-
Converting Enzyme-Processed Peptides in Mouse Plasma. *Anal Chem* 91: 6440-6453
Skirgello OE, Binevski PV, Pozdnev VF, Kost OA (2005) Kinetic probes for inter-domain co-operation in
human somatic angiotensin-converting enzyme. *Biochem J* 391: 641-647
Tang WJ (2016) Targeting Insulin-Degrading Enzyme to Treat Type 2 Diabetes Mellitus. *Trends*
Endocrinol Metab 27: 24-34
Tang WS, Zhong ED, Hanson SM, Thiede EH, Cossio P (2023) Conformational heterogeneity and
probability distributions from single-particle cryo-electron microscopy. *Curr Opin Struc Biol* 81
Turner AJ, Hooper NM (2002) The angiotensin-converting enzyme gene family: genomics and
pharmacology. *Trends Pharmacol Sci* 23: 177-183
Wright JW, Kawas LH, Harding JW (2013) A Role for the Brain RAS in Alzheimer's and Parkinson's
Diseases. *Front Endocrinol (Lausanne)* 4: 158
Yu XC, Sturrock ED, Wu Z, Biemann K, Ehlers MR, Riordan JF (1997) Identification of N-linked
glycosylation sites in human testis angiotensin-converting enzyme and expression of an active
deglycosylated form. *J Biol Chem* 272: 3511-3519
Zhang Y, Chen H, Li R, Sterling K, Song W (2023) Amyloid beta-based therapy for Alzheimer's disease:
challenges, successes and future. *Signal Transduct Target Ther* 8: 248
Zhang ZN, Liang WGG, Bailey LJ, Tan YZ, Wei H, Wang A, Farcasanu M, Woods VA, McCord LA, Lee D
et al (2018) Ensemble cryoEM elucidates the mechanism of insulin capture and degradation by
human insulin degrading enzyme. *Elife* 7: e33572
Zheng WY, Tian EK, Liu Z, Zhou CH, Yang P, Tian KY, Liao W, Li J, Ren CY (2022) Small molecule
angiotensin converting enzyme inhibitors: A medicinal chemistry perspective. *Front Pharmacol* 13
Zou K, Maeda T, Watanabe A, Liu JJ, Liu SY, Oba R, Satoh Y, Komano H, Michikawa M (2009) A beta 42-
to-A beta 40-and Angiotensin-converting Activities in Different Domains of Angiotensin-converting
Enzyme. *J Biol Chem* 284: 31914-31920

790